ArticleScientific reports2025
Enhancing pharmacokinetic properties of Chikusetsusaponin IVa via modification of polyethylenimine/poly(lactic-co-glycolic acid) nanoparticles for sustained drug delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Distinguishing pharmacokinetic enhancements of novel drug delivery systems from conventional formulations is critical for optimizing therapeutic outcomes of poorly soluble drugs like Chikusetsusaponin IVa (CHIVA), which suffers from low aqueous solubility and limited oral bioavailability. We optimized polyethyleneimine (PEI)-modified poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles for CHIVA delivery using response surface methodology (RSM) and the double emulsion-solvent evaporation method, varying PEI (0.25-0.75%), PLGA (1.5-4.5%), and CHIVA (2-4 mg/mL) concentrations. Optimized nanoparticles (0.5% PEI, 3% PLGA, 3 mg/mL CHIVA) achieved an encapsulation efficiency of 86 ± 1.3%, drug loading of 2.201 ± 0.201%, particle size of 222 ± 11 nm, and zeta potential of 3.9 ± 0.6 mV, with sustained CHIVA release over 132 h fitting a first-order kinetic model (R
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.